Regenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

Go back to Regenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

August 4, 2020 7:00 AM EDT

ROCKVILLE, Md., Aug. 4, 2020 /PRNewswire/ --

Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020 RGX-314 was generally well-tolerated in 42 patients at all dose levels in Phase I/IIa trial Positive interim update from Cohorts 4 and 5 at one year informs pivotal program Durable treatment effect observed with stable to improved visual acuity and retinal thickness Demonstrated meaningful reductions in anti-VEGF treatment burden over one year 61% and 85% reduction of anti-VEGF injections in Cohorts 4 and 5, respectively... More